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http://www.biomedcentral.com/1471-2474/15/437RESEARCH ARTICLE Open AccessElevated VEGF levels contribute to the
pathogenesis of osteoarthritis
Quan Yuan1*, Li Sun2, Jian-Jun Li1 and Chun-Hou An1Abstract
Background: The aim of our meta-analysis is to understand the relationship between the pathogenesis of
osteoarthritis and the expression levels of vascular endothelial growth factor (VEGF) in multiple disease tissues
in osteoarthritis patients.
Methods: The following electronic databases were searched, without language restrictions, to retrieve published
studies relevant to VEGF and osteoarthritis: MEDLINE (1966 ~ 2013), the Cochrane Library Database (Issue 12, 2013),
EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), Web of Science (1945 ~ 2013) and the Chinese Biomedical Database
(CBM) (1982 ~ 2013). Meta-analysis of the extracted data was performed using the STATA statistical software.
Standardized mean difference (SMD) with its corresponding 95% confidence interval (95% CI) was calculated.
Results: A total of 11 case–control studies, containing 302 osteoarthritis patients and 195 healthy controls,
met our selection criteria for this meta-analysis. Our analyses of the data available from multiple disease tissues
demonstrate that VEGF expression levels in osteoarthritis patients are significantly higher than healthy controls
(SMD = 1.18, 95% CI: 4.91 ~ 9.11, P < 0.001). A subgroup analysis based on ethnicity revealed that both Asian
and Caucasian osteoarthritis patients had higher levels of VEGF expression compared to their respective healthy
counterparts (Asians: SMD = 5.49, 95% CI: 3.44 ~ 7.54, P < 0.001; Caucasians: SMD = 15.17, 95% CI: 5.21 ~ 25.13, P = 0.003;
respectively). We also performed other subgroup analyses based on country, language and sample source, and the
results showed that, in all these subgroups, osteoarthritis patients had higher levels of VEGF expression than
healthy controls (all P > 0.05).
Conclusion: Our meta-analysis provides evidence that higher VEGF expression levels strongly correlate with
the pathogenesis of osteoarthritis.
Keywords: Vascular endothelial growth factor, Osteoarthritis, Pathogenesis, Meta-analysisBackground
Osteoarthritis is a common age-related degenerative mus-
culoskeletal disease, which is associated with declining
joint functions, muscle volume and power, with serious im-
pact on daily activities and quality of life [1,2]. In osteo-
arthritis, a breakdown of the extracellular matrix (ECM) of
articular cartilage occurs in the affected joints, and the dis-
ease pathogenesis involves cartilage destruction, bone re-
modeling and inflammation of the synovial membrane.
Osteoarthritis is the most prevalent of chronic rheumatic
diseases worldwide, affecting approximately 40% of people
over 70 years in age, and is the fourth leading cause of* Correspondence: yuanquanyq127@163.com
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unless otherwise stated.disability [3-5]. As the world population is aging, the inci-
dence and prevalence of osteoarthritis is rapidly increasing
and is placing an enormous burden on the health care sys-
tems across the world [6]. Epidemiological studies have
identified various risk factors in the pathogenesis of osteo-
arthritis, including age, sex, race, and obesity [7,8]. Import-
antly, molecular mechanisms involved in osteoarthritis
progression have been the subject of interest for discovery
of new pathways and for development of novel strategies
for disease modification [9,10]. In this context, the vascula-
ture has an essential role in osteogenesis, skeletal develop-
ment and bone fracture repair [9], and in osteoarthritis,
disturbances in blood flow due to altered vasculature can
have devastating effects on cell survival and fluid drainage.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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http://www.biomedcentral.com/1471-2474/15/437Vascular endothelial growth factor (VEGF) is a potent
angiogenic factor and a critical regulator of angiogenesis
in skeletal development and bone remodeling, and VEGF
is suspected to play an active role in the pathogenesis of
osteoarthritis [11]. VEGF functions as a homodimer and is
a highly glycosylated protein of 46–48 kDa, with strong
angiogenic activity, and elicits mitogenic and chemotactic
responses in endothelial cells [12]. VEGF is considered to
be a potent, multifunctional cytokine with important bio-
logical effects on the vascular endothelium [13]. VEGF
mediated blood vessel formation regulates angiogenesis,
vasculogenesis, vascular permeability, and in adult angio-
genesis, is important in skeletal development and in
bone fracture repair [14,15]. In the context of osteogen-
esis, VEGF secretion is not only important for stimulation
of endothelial cells to undergo proliferation, migration,
differentiation and tube formation [16], but also VEGF ac-
tivities promote bone formation and bone healing by dir-
ectly influencing the survival, chemotactic migration and
activity of osteoblasts [11]. VEGF has three major effects
on bone development: (a) induction of angiogenesis in
intramembranous or enchondral bone development, (b)
chemotactic migration of osteoclastic cells to the hyper-
trophic cartilage and osteoblastic activation, and (c) direct
effects on osteoprogenitor cells by promoting differenti-
ation to osteoblast and increasing mineralization of
the regenerated bone [17]. Therefore, the pro-angiogenic
cytokine VEGF is a promising biomarker for diagnosis of
osteoarthritis and also a prime therapeutic target [11].
There is evidence supporting that high VEGF levels in
both plasma and synovial fluids are positively correlated
with the radiographic severity of knee osteoarthritis, sug-
gesting increased expression of VEGF occurs in osteoarth-
ritis cartilage, and this may stimulate the growth of blood
vessels from subchondral bone into articular cartilage,
thereby contributing to osteoarthritis progression [18].
However, other studies found no significant association
between VEGF and osteoarthritis [18,19]. In view of the
conflicting results, we performed a meta-analysis to evalu-
ate relationship between increased VEGF expression and
the pathogenesis of osteoarthritis.
Methods
Literature search and selection criteria
The following electronic databases were searched without
language restrictions: MEDLINE (1966~ 2013), the Cochrane
Library Database (Issue 12, 2013), EMBASE (1980~ 2013),
CINAHL (1982 ~ 2013), Web of Science (1945 ~ 2013)
and the Chinese Biomedical Database (CBM) (1982 ~
2013). We used the following keywords and MeSH terms
in conjunction with a highly sensitive search strategy:
[“osteoporosis” or “juvenile osteoporosis” or “age-related
osteoporosis” or “age-related bone loss”] and [“osteoarth-
ritis, spine” or “osteoarthritis, knee” or “osteoarthritis” or“coxarthrosis”] and [“vascular endothelial growth factors”
or “VEGF” or “vascular endothelial growth factor” or “vas-
cular permeability factor” or “VPF”]. We also conducted a
manual search to identify other relevant articles from
cross-references.
The following inclusion criteria were employed for the
eligibility of studies in our meta-analysis: (1) the study
design must be clinical case–control focused on the rela-
tionships of VEGF expression levels with pathogenesis of
osteoarthritis; (2) all patients met diagnostic criteria for
osteoarthritis; (3) the study must provide sufficient infor-
mation about VEGF expression levels. If the study could
not meet the inclusion criteria, it would be excluded.
The most recent study or the study with the largest sam-
ple size was included when the authors published several
studies using the same subjects.
Data extraction and methodological assessment
Data was extracted from the included studies by two au-
thors using a standardized form. The form used for data
extraction documented the most relevant items including
language of publication, publication year of article, the first
author’s surname, geographical location, design of study,
sample size, source of the subjects, VEGF expression levels,
source of samples, and detection method.
Methodological quality was evaluated separately by
two observers using the Newcastle-Ottawa Scale (NOS)
criteria [20]. The NOS criteria included three aspects:
(1) subject selection: 0–4; (2) comparability of subject:
0–2; (3) clinical outcome: 0–3. NOS scores ranged from
0 to 9; and a score ≥ 7 indicate a good quality.
Statistical analysis
Meta-analysis was performed using the STATA statistical
software (Version 12.0, Stata Corporation, College Station,
TX, USA). Standardized mean difference (SMD) with its
corresponding 95% confidence interval (95% CI) was
calculated. The Z test was used to estimate the statistical
significance of pooled SMDs. Heterogeneity among stud-
ies were estimated by the Cochran’s Q-statistic and I2 tests
[21]. If Q-test shows a P < 0.05 or I2 test exhibits > 50%,
which indicates significant heterogeneity, the random-
effect model was employed, or else the fixed-effects model
was used. We also tested for the source of heterogeneity
using subgroup analyses. In order to evaluate the influence
of single studies on the overall estimate, a sensitivity ana-
lysis was performed. Begger's test and Egger's test were
applied to investigate publication bias [22].
Results
Study selection and basic characteristics of the included
studies
Our highly sensitive search strategy retrieved 233 articles.
After reviewing the titles and abstracts of all the articles,
Figure 1 Flow chart shows study selection procedure. Eleven case–control studies were included in this meta-analysis.
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articles were reviewed and 105 articles were further ex-
cluded. In addition, 2 studies were excluded due to lack of
data integrity (Figure 1). Finally, 11 case–control studies
involving a total of 302 osteoarthritis patients and 195Table 1 Main characteristics and methodological quality of al
First author Year Country Language Ethnicity Gender (M/F
Case Contr
Saetan et al. [18] 2013 Thailand English Asians 17/63 5/15
Zhu et al. [26] 2012 China Chinese Asians 8/10 6/4
Duan et al. [24] 2011 China English Asians 8/22 6/4
Huh et al. [28] 2010 Korea English Asians - -
Chen et al. [23] 2009 China Chinese Asians 11/19 7/1
Su et al. [25] 2008 China Chinese Asians 8/12 7/3
Fay et al. [3] 2006 Germany English Caucasians - -
Enomoto et al. [27] 2003 Japan English Asians - -
Pfander et al. [30] 2001 Germany English Caucasians - -
Lee et al. [29] 2001 Korea English Asians 4/45 -
Ballara et al. [19] 2001 Germany English Caucasians 15/17 11/2
M: male; F: female; NOSF: Newcastle-Ottawa Scale; VEGF: vascular endothelial growthealthy controls met our inclusion criteria for qualitative
data analysis [3,18,19,23-30]. These studies were published
between 1998 and 2013. Overall, 8 studies were conducted
among Asians, and 3 studies among Caucasians. Enzyme-
linked immunosorbent assay (ELISA) method was used inl eligible studies




69.8 ± 0.9 68.2 ± 1.1 ELISA VEGF Plasma 7
65 22 ELISA VEGF Synovial fluid 6
62 (50 ~ 76) 32 ELISA VEGF Synovial tissue 6
74.0 ± 9.0 61.5 ± 15.6 ELISA VEGF Cartilaginous
tissue
5
(52 ~ 75) (21 ~ 43) ELISA VEGF Synovial tissue 6
60 45 ELISA VEGF Cartilaginous
tissue
6
- - ELISA VEGF Synovial fluid 5
72.0 ± 8.0 79.0 ± 9.0 ELISA VEGF Cartilaginous
tissue
5
- - ELISA VEGF Cartilaginous
tissue
5
59.6 ± 1.1 - ELISA VEGF Plasma 5
0 55 (50 ~ 65) 49 (38 ~ 55) ELISA VEGF Plasma 6
h factor; ELISA: enzyme-linked immunosorbent assay.
Figure 2 Forest plots for the relationships between VEGF expression levels and the pathogenesis of osteoarthritis.
Figure 3 Subgroup analyses by ethnicity, country, language and sample source of the relationships between VEGF expression levels
and the pathogenesis of osteoarthritis.
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VEGF expression levels in 3 studies, 4 studies used cartil-
aginous tissues, 2 studies used synovial tissues and 2 stud-
ies used synovial fluid. NOS scores of all included studies
were ≥ 5. We summarized the study characteristics and
methodological quality in Table 1.
Quantitative data synthesis
The random effects model was employed since signifi-
cant heterogeneity existed between studies (I2 = 96.5%,
P < 0.001). The results of our meta-analysis revealed that
VEGF expression levels in osteoarthritis patients were sig-
nificantly higher than healthy controls (SMD= 7.01, 95%Figure 4 Sensitivity analysis and publication bias evaluation of the su
expression levels and the pathogenesis of osteoarthritis.CI: 4.91 ~ 9.11, P < 0.001) (Figure 2). A subgroup analysis
based on ethnicity, revealed that both Asian and Caucasian
osteoarthritis patients had higher levels of VEGF expression
than healthy controls(Asians: SMD= 5.49, 95% CI: 3.44 ~
7.54, P < 0.001; Caucasians: SMD= 15.17, 95% CI: 5.21 ~
25.13, P = 0.003; respectively) (Figure 3). We performed
other subgroup analyses based on country, language and
sample source. The results also suggested that osteoarth-
ritis patients had higher levels of VEGF expression than
healthy controls in all the subgroups (all P > 0.05). Sensitiv-
ity analysis suggested that no single study could influence
the pooled ORs (Figure 4). Funnel plots demonstrated no
evidence of asymmetry. Egger’s test also did not displaymmary estimate coefficients on the relationships between VEGF
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(Figure 4).
Discussion
We investigated the relationship between steady-state
VEGF levels and osteoarthritis. Our meta-analysis showed
a positive association of VEGF expression levels with
osteoarthritis, implying that VEGF may play an important
role in osteoarthritis progression. Environmental, bio-
mechanical and biological factors, such as growth factors,
play a substantial role in the development of osteoarthritis
[31]. Although VEGF’s role is suspected, the precise mech-
anism by which VEGF levels influence osteoarthritis re-
mains largely unknown. We hypothesize that increased
local production of VEGF plays a pivotal role in endochon-
dral ossification by coupling angiogenesis with hypertrophic
cartilage remodelling and endochondral bone formation,
through acting on osteoblasts [27]. VEGF expression is also
upregulated in inflammatory arthritis, suggesting VEGF
may have specific roles in angiogenesis and inflammation,
which are closely related processes in osteoarthritis [32].
Our meta-analysis finding is in accordance with a previous
study that demonstrated increased VEGF expression by
chondrocytes in osteoarthritic articular cartilage, suggest-
ing chondrocyte involvement in articular cartilage de-
struction and development of osteoarthritis [3]. Consistent
with the argument for an important role of VEGF in osteo-
arthritis, Gallelli et al. showed that ibuprofen, diclofenac
and celecoxib decrease VEGF levels in the synovial fluid of
the osteoarthritic joint, with a concomitant improvement
in joint pain as well as joint function in osteoarthritis pa-
tients [33]. Thus, VEGF could serve as a promising bio-
marker to assessdisease severity in osteoarthritis, and
could be the basis for targeted clinical treatments.
In order to understand the correlations between VEGF
expression levels and osteoarthritis, we performed sub-
group analyses based on ethnicity, country, language and
sample source. Our meta-analysis results conclusively
showed that the expression levels of VEGF were signifi-
cantly higher in osteoarthritis patients than healthy con-
trols in all these subgroups, indicating the high value of
VEGF as a reliable disease biomarker VEGF plays an im-
portant role in bone formation, mineralization, and re-
modeling, by acting directly on the differentiation and
survival of osteoblasts [34]. Consistent with this, inhib-
ition of VEGF mediated signaling by neutralization of
VEGF receptor decreased angiogenesis, bone forma-
tion and callus mineralization in experimental animal
models, suggesting the significant potential of the VEGF
pathway in addressing bone diseases [9,11]. However,
strategies that involve inhibition of VEGF pathways must
also be approached with caution due to the central role
played by VEGF in many normal cellular processes. For
example, by promoting endothelial cells proliferation,VEGF enhances vascular permeability, and thereby con-
tributes to blood vessel formation in the bone, which is an
important step in the healing of osteoporotic bone [35,36].
Also, interestingly, decreased secretion of VEGF, causes
increased intracellular accumulation of VEGF, and is im-
portant in osteoblast and adipocyte differentiation choice,
and an imbalance could potentially contribute to the
severity and progression of osteoarthritis [37]. Martinez
et al. observed an age-related decrease in secreted VEGF
in osteoblasts, implicating VEGF as the modulating factor
for bone remodeling in patients with osteoarthritis [38].
Taken together, we speculate that VEGF plays an import-
ant role in normal bone growth and in the pathogenesis of
osteoarthritis, and is a promising biomarker for determin-
ing the disease severity in osteoarthritis.
The current meta-analysis also had several limitations
that should be mentioned. First, our results lack sufficient
statistical power to assess the correlations of VEGF
expression levels with the pathogenesis of osteoarthritis
due to the small number of studies. The small number of
studies may restrict general applications of our findings,
and consequently our meta-analysis should be regarded as
preliminary. Second, since we only included studies
written in English and Chinese, a potential selection bias
cannot be totally excluded. Third, we could not investigate
the detailed evaluation of VEGF in the pathogenesis of
osteoarthritis due to the lack of original data in the
included studies.
Conclusion
In conclusion, our meta-analysis revealed that VEGF ex-
pression levels strongly correlate with the pathogenesis
of osteoarthritis. Thus, we believe VEGF should be con-
sidered as a promising biomarker to assess disease sever-
ity in osteoarthritis, and could be the basis for targeted
treatments in the future. However, due to the limitations
in our current study, larger sample size and more de-
tailed information are required to conclusively prove our
findings in this meta-analysis.
Additional file
Additional file 1: MOOSE guidelines for reporting meta-analysis
observational studies in epidemiology.
Abbreviations
VEGF: Vascular endothelial growth factor; CBM: Chinese Biomedical Database;
SMD: Standardized mean difference; 95% CI: 95% confidence interval;
ECM: Extracellular matrix; ELISA: Enzyme-linked immunosorbent assay.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
QY designed and carried out most of data and wrote manuscript. LS, J-J L
and C-H A performed proofreading of manuscript, and wrote the
manuscript.
Yuan et al. BMC Musculoskeletal Disorders 2014, 15:437 Page 7 of 8
http://www.biomedcentral.com/1471-2474/15/437Supporting Information
Our manuscript reporting adheres to MOOSE guidelines for reporting
meta-analysis observational studies in epidemiology.The supporting MOOSE
Checklist is available as supplementary information; see Additional file 1.
Acknowledgments
We would like to acknowledge the reviewers for their helpful comments on
this paper.
Author details
1Department of Orthopedics, Shengjing Hospital of China Medical University,
Sanhao Street No. 36, Heping District, Shenyang 110004, P.R. China.
2Department of Nephrology, The First Affiliated Hospital of China Medical
University, Shenyang 110001, P.R. China.
Received: 18 August 2014 Accepted: 11 December 2014
Published: 17 December 2014
References
1. Zhang ZM, Li ZC, Jiang LS, Jiang SD, Dai LY: Micro-CT and mechanical
evaluation of subchondral trabecular bone structure between
postmenopausal women with osteoarthritis and osteoporosis.
Osteoporos Int 2010, 21(8):1383–1390.
2. Jin WJ, Jiang SD, Jiang LS, Dai LY: Differential responsiveness to
17beta-estradiol of mesenchymal stem cells from postmenopausal
women between osteoporosis and osteoarthritis. Osteoporos Int 2012,
23(10):2469–2478.
3. Fay J, Varoga D, Wruck CJ, Kurz B, Goldring MB, Pufe T: Reactive oxygen
species induce expression of vascular endothelial growth factor in
chondrocytes and human articular cartilage explants. Arthritis Res Ther
2006, 8(6):R189.
4. Young DA, Bui C, Barter MJ: Understanding CpG methylation in the
context of osteoarthritis. Epigenomics 2012, 4(6):593–595.
5. Fransen M, Bridgett L, March L, Hoy D, Penserga E, Brooks P: The epidemiology
of osteoarthritis in Asia. Int J Rheum Dis 2011, 14(2):113–121.
6. Prieto-Alhambra D, Nogues X, Javaid MK, Wyman A, Arden NK, Azagra R,
Cooper C, Adachi JD, Boonen S, Chapurlat RD, Compston JE, Gehlbach SH,
Greenspan SL, Hooven FH, Netelenbos JC, Pfeilschifter J, Rossini M,
Sambrook PN, Silverman S, Siris ES, Watts NB, Diez-Perez A: An increased
rate of falling leads to a rise in fracture risk in postmenopausal women
with self-reported osteoarthritis: a prospective multinational cohort
study (GLOW). Ann Rheum Dis 2013, 72(6):911–917.
7. Neogi T, Zhang Y: Epidemiology of osteoarthritis. Rheum Dis Clin North Am
2013, 39(1):1–19.
8. Loeser RF, Goldring SR, Scanzello CR, Goldring MB: Osteoarthritis: a disease
of the joint as an organ. Arthritis Rheum 2012, 64(6):1697–1707.
9. Corrado A, Neve A, Cantatore FP: Expression of vascular endothelial
growth factor in normal, osteoarthritic and osteoporotic osteoblasts.
Clin Exp Med 2013, 13(1):81–84.
10. Giner M, Montoya MJ, Vazquez MA, Miranda C, Perez-Cano R: Differences in
osteogenic and apoptotic genes between osteoporotic and osteoarthritic
patients. BMC Musculoskelet Disord 2013, 14:41.
11. Neve A, Cantatore FP, Corrado A, Gaudio A, Ruggieri S, Ribatti D: In vitro
and in vivo angiogenic activity of osteoarthritic and osteoporotic
osteoblasts is modulated by VEGF and vitamin D3 treatment. Regul Pept
2013, 184:81–84.
12. Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M: Vasopressin induces
human mesangial cell growth via induction of vascular endothelial
growth factor secretion. Neuropeptides 2011, 45(2):105–111.
13. Poh CK, Shi Z, Lim TY, Neoh KG, Wang W: The effect of VEGF
functionalization of titanium on endothelial cells in vitro.
Biomaterials 2010, 31(7):1578–1585.
14. Cui Q, Dighe AS, Irvine JN Jr: Combined angiogenic and osteogenic factor
delivery for bone regenerative engineering. Curr Pharm Des 2013,
19(19):3374–3383.
15. Bates DO: Vascular endothelial growth factors and vascular permeability.
Cardiovasc Res 2010, 87(2):262–271.
16. Wise LM, Inder MK, Real NC, Stuart GS, Fleming SB, Mercer AA: The vascular
endothelial growth factor (VEGF)-E encoded by orf virus regulates
keratinocyte proliferation and migration and promotes epidermal
regeneration. Cell Microbiol 2012, 14(9):1376–1390.17. Cebi H, Aksahin E, Yuksel HY, Celebi L, Aktekin CN, Hapa O, Muratli HH,
Bicimoglu A: Plasma vascular endothelial growth factor levels are similar
in subjects with and without osteoporosis. Eklem Hastalik Cerrahisi 2010,
21(2):91–97.
18. Saetan N, Honsawek S, Tanavalee A, Yuktanandana P, Meknavin S,
Ngarmukos S, Tanpowpong T, Parkpian V: Relationship of plasma and
synovial fluid vascular endothelial growth factor with radiographic
severity in primary knee osteoarthritis. Int Orthop 2013, 38(5):1099-104
19. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM:
Raised serum vascular endothelial growth factor levels are associated
with destructive change in inflammatory arthritis. Arthritis Rheum 2001,
44(9):2055–2064.
20. Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment
of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol
2010, 25(9):603–605.
21. Zintzaras E, Ioannidis JP: HEGESMA: genome search meta-analysis and
heterogeneity testing. Bioinformatics 2005, 21(18):3672–3673.
22. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L: Comparison of
two methods to detect publication bias in meta-analysis. JAMA 2006,
295(6):676–680.
23. Chen NJ: Expression of vascular endothelial growth factor and
transforming growth factor-beta1 in synovial membrance of osteoarthritis
and their relationships. J Clin Rehabilitative Tissue Engineering Re 2009,
13(2):288–291.
24. Duan X, Li Q, Li LJ, Liu CL, Li ZH, Li DJ, Zhang F: Expression of
hypoxia-inducible factor-1α and vascular endothelial growth factor
in the synovium of patients with osteoarthritis. J Southern Med Univ
2011, 31(1):117–120.
25. Su W, Xie W, Guan M: [Detection of vascular endothelial growth factor in
patients with osteoarthritis]. Labor Med 2008, 23(1):42–46.
26. Zhu BY, Wang QY, Wu B, Wang WC, Tian J: The significance of IL-6 and
VEGF expression in patients with knee osteparthritis. Chin J Gerontol
2012, 2:273–275.
27. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, Matsumoto H,
Toyama Y, Okada Y: Vascular endothelial growth factor isoforms and their
receptors are expressed in human osteoarthritic cartilage. Am J Pathol
2003, 162(1):171–181.
28. Huh JE, Seo DM, Baek YH, Choi DY, Park DS, Lee JD: Biphasic positive
effect of formononetin on metabolic activity of human normal and
osteoarthritic subchondral osteoblasts. Int Immunopharmacol 2010,
10(4):500–507.
29. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY: Vascular
endothelial growth factor levels in the serum and synovial fluid
of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001,
19(3):321–324.
30. Pfander D, Kortje D, Zimmermann R, Weseloh G, Kirsch T, Gesslein M,
Cramer T, Swoboda B: Vascular endothelial growth factor in articular
cartilage of healthy and osteoarthritic human knee joints. Ann Rheum Dis
2001, 60(11):1070–1073.
31. Nishimura A, Hasegawa M, Kato K, Yamada T, Uchida A, Sudo A: Risk factors
for the incidence and progression of radiographic osteoarthritis of the
knee among Japanese. Int Orthop 2011, 35(6):839–843.
32. Hashimoto S, Creighton-Achermann L, Takahashi K, Amiel D, Coutts RD, Lotz M:
Development and regulation of osteophyte formation during experimental
osteoarthritis. Osteoarthritis Cartilage 2002, 10(3):180–187.
33. Gallelli L, Galasso O, Falcone D, Southworth S, Greco M, Ventura V, Romualdi P,
Corigliano A, Terracciano R, Savino R, Gulletta E, Gasparini G, De Sarro G:
The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes,
synovial fluid cytokine concentration and signal transduction pathways in
knee osteoarthritis. A randomized open label trial. Osteoarthritis Cartilage/
OARS, Osteoarthritis Res Soc 2013, 21:1400–1408.
34. Kasten P, Beverungen M, Lorenz H, Wieland J, Fehr M, Geiger F:
Comparison of platelet-rich plasma and VEGF-transfected mesenchymal
stem cells on vascularization and bone formation in a critical-size bone
defect. Cells Tissues Organs 2012, 196(6):523–533.
35. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K: VEGF and angiopoietin
signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011,
17(7):347–362.
36. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni
I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD: VEGF-
induced vascular permeability is mediated by FAK. Dev Cell 2012, 22(1):146–157.
Yuan et al. BMC Musculoskeletal Disorders 2014, 15:437 Page 8 of 8
http://www.biomedcentral.com/1471-2474/15/43737. Liu Y, Berendsen AD, Jia S, Lotinun S, Baron R, Ferrara N, Olsen BR:
Intracellular VEGF regulates the balance between osteoblast and
adipocyte differentiation. J Clin Invest 2012, 122(9):3101–3113.
38. Martinez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martinez ME: Age-related
changes in parathyroid hormone-related protein and vascular endothelial
growth factor in human osteoblastic cells. Osteoporos Int 2002,
13(11):874–881.
doi:10.1186/1471-2474-15-437
Cite this article as: Yuan et al.: Elevated VEGF levels contribute to the
pathogenesis of osteoarthritis. BMC Musculoskeletal Disorders 2014 15:437.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
